問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taichung Veterans General Hospital (在職)

Division of General Internal Medicine

Division of Hematology & Oncology

Division of Thoracic Medicine

Division of Thoracic Surgery

更新時間：2025-10-29

楊宗穎YANG, TSUNG -YING
  • Principal Investigator
  • Clinical Trial Experience (year)

  • jonyin@gmail.com

Recruiting Trial

134Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

楊宗穎

Taichung Veterans General Hospital

Division of Thoracic Medicine

List

180Cases

2024-05-15 - 2032-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting3Sites

Recruiting3Sites

2018-12-01 - 2019-11-07

Phase I

Active
A Phase I Multicenter Study of Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (CLOVER)

  • Condition/Disease

    Carcinoma, Squamous Cell of Head and Neck Carcinoma, Non-Small-Cell Lung Small Cell Lung Carcinoma

  • Test Drug

    Durvalumab (MEDI4736) / Tremelimumab

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting3Sites

羅永鴻
Taipei Veterans General Hospital

Division of Thoracic Medicine

2023-10-05 - 2029-04-30

Phase III

Active
A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed Versus Platinum plus Pemetrexed or Nivolumab plus Ipilimumab in Participants with Unresectable Pleural Mesothelioma (eVOLVE-Meso)

  • Condition/Disease

    Unresectable Pleural Mesothelioma

  • Test Drug

    Volrustomig (MEDI5752)OPDIVO (nivolumab)YERVOY (ipilimumab)Pemetrexed AccordCarboplatin HikmaCisplatinum Accord

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

2019-04-01 - 2025-12-31

Phase II

Active
A Phase II, Single Arm Study Assessing Efficacy of Osimertinib With Savolitinib in Patients With EGFRm+ MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Progressed Following Osimertinib Treatment (SAVANNAH Study)

  • Condition/Disease

    Locally Advanced or Metastatic Non Small Cell Lung Cancer

  • Test Drug

    TAGRISSO and Savolitinib

Participate Sites
10Sites

Recruiting10Sites

2018-12-01 - 2024-12-31

Phase III

Active
A Phase III, Randomised,Double-Blind,Placebo-Controlled,Study of Durvalumab as Consolidation Therapy in Patients With Locally Advanced,Unresectable NSCLC, Who Have Not Progressed Following Definitive, Platinum-Based Chemoradiation Therapy

  • Condition/Disease

    Non-Small Cell Lung Cancer

  • Test Drug

    Durvalumab (MEDI4736)

Participate Sites
7Sites

Recruiting3Sites

Terminated4Sites

李岡遠
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

2018-10-01 - 2026-12-31

Phase III

Active
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Stage I-III Limited Disease Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)

  • Condition/Disease

    Small Cell Lung Cancer

  • Test Drug

    Durvalumab (MEDI4736)

Participate Sites
11Sites

Recruiting10Sites

Terminated1Sites

張文震
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

李岡遠
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

2022-09-15 - 2026-09-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2015-07-01 - 2019-07-31

Phase III

Completed
A Phase III, Multi-Centre, Open Label, Randomized Study to Assess the Efficacy and Safety of AZD9291 in Combination with MEDI4736 versus AZD9291 Monotherapy in Patients with Locally Advanced or Metastatic Epidermal Growth Factor Receptor T790M mutation-positive Non-Small Cell Lung Cancer who have received Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy (CAURAL)

  • Condition/Disease

    Non-Small Cell Lung Cancer

  • Test Drug

    AZD9291 / MEDI4736

Participate Sites
4Sites

Terminated4Sites

2021-12-01 - 2032-12-31

Phase III

Active
A Phase III, Double-blind, Randomised, Placebo-Controlled, International Study to Assess the Efficacy and Safety of Adjuvant Osimertinib Versus Placebo in Participants With EGFR Mutation-positive Stage IA2-IA3 Non-small Cell Lung Cancer, Following Complete Tumour Resection

  • Condition/Disease

    Non-Small Cell Lung Cancer

  • Test Drug

    TAGRISSO Film-coated Tablets 40 mg/ TAGRISSO Film-coated Tablets 80 mg

Participate Sites
8Sites

Recruiting8Sites

2022-05-01 - 2028-06-30

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

1 2 3 4 5 18
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB